Patents Examined by Gary L. Kunz
-
Patent number: 6489288Abstract: Agents which increase the levels of human insulin-like growth factor—1 binding protein (h-IGFBP-1), such as an estrogen, are used in conjunction with a gonadotropin releasing hormone (GnRH) analogue in the treatment of PCOD and associated infertility.Type: GrantFiled: February 16, 1994Date of Patent: December 3, 2002Assignee: Applied Research Systems ARS HoldingInventor: Bruno Lunenfeld
-
Patent number: 6486122Abstract: Disclosed are peptides related to human TGF-&agr;, having TGF-&agr; biological activity, which are useful for many of the indications that full-length TGF-&agr; polypeptide is useful. Also provided are methods of use of such peptides, as well as human TGF-&agr; and biologically related polypeptides. For example, methods for treating or preventing cachexia in subjects are provided as well as methods for stimulating hematopoiesis in patients undergoing cytotoxic chemotherapy. In addition, the use of TGF-&agr; related peptides to related neurodengenerative diseases is also provided. Methods of the invention also provide protection for patients undergoing cytotoxic therapy from side effects such as gastrointestinal (GI) mucositis.Type: GrantFiled: April 26, 2000Date of Patent: November 26, 2002Assignee: Stem Cell Pharmaceuticals, Inc.Inventors: Daniel R. Twardzik, Stefan Paskell, Thomas S. Felker
-
Patent number: 6485919Abstract: In accordance with the present invention, there are provided nucleic acids encoding human metabotropic glutamate receptor subtypes and the proteins encoded thereby. In a particular embodiment, the invention nucleic acids encode mGluR1, mGluR2, mGluR3 and mGluR5 subtypes of human metabotropic glutamate receptors. In addition to being useful for the production of metabotropic glutamate receptor subtypes, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits. In addition to disclosing novel metabotropic glutamate receptor subtypes, the present invention also comprises methods for using such receptor subtypes to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function.Type: GrantFiled: December 13, 1999Date of Patent: November 26, 2002Assignee: Merck & Co., Inc.Inventors: Lorrie Daggett, Steven B. Ellis, Chen Liaw, Aaron Pontsler, Edwin C. Johnson, Stephen D. Hess
-
Patent number: 6482796Abstract: Improved therapeutic uses for N-terminal BPI protein products are described in patients that have BPI-reactive anti-neutrophil cytoplasmic antibodies.Type: GrantFiled: February 22, 1999Date of Patent: November 19, 2002Assignee: Xoma CorporationInventor: Stephen Fitzhugh Carroll
-
Patent number: 6482410Abstract: The present invention relates to cytotactin proteins, polypeptides, antibodies (including anti-idiotype antibodies), and other cytotacting derivatives useful in the mediation of neuronal attachment and enhancement of the outgrowth of neurites, as well as to methods of using same. Methods of making the disclosed proteins, polypeptides, antibodies, derivatives and related compositions, which have a variety of diagnostic and therapeutic applications, are also disclosed.Type: GrantFiled: May 22, 1997Date of Patent: November 19, 2002Assignee: The Scripps Research InstituteInventors: Kathryn L. Crossin, Greg Phillips, Anne L. Prieto
-
Patent number: 6482608Abstract: In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor (CRF) such that concentrations of 10 nM of CRF occupy 50% of the binding sites of said receptor protein. Nucleic acid sequences encoding such receptors, assays employing same, as well as antibodies derived therefrom, are also disclosed. Invention CRF-Rs can be employed in a variety of ways, such as, for example, in bioassays, for production of antibodies thereto, in therapeutic compositions containing such proteins and/or antibodies.Type: GrantFiled: May 26, 2000Date of Patent: November 19, 2002Assignee: The Salk Institute for Biological StudiesInventors: Marilyn H. Perrin, Ruoping Chen, Kathy A. Lewis, Wylie W. Vale, Jr., Cynthia J. Donaldson, Paul Sawchenko
-
Patent number: 6479630Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel purinergic PU2 receptor (PNR) expressed in human placenta. The present invention also provides for antisense molecules to the nucleotide sequences which encode PNR, expression vectors for the production of purified PNR, antibodies capable of binding specifically to PNR, hybridization probes or oligonucleotides for the detection of PNR-encoding nucleotide sequences, genetically engineered host cells for the expression of PNR, and diagnostic tests based on PNR-encoding nucleic acid molecules or antibodies produced against the polypeptide PNR.Type: GrantFiled: June 22, 1998Date of Patent: November 12, 2002Assignee: Incyte GenomicsInventors: Roger Coleman, Janice Au-Young, Susan G. Stuart, Karl J. Guegler
-
Patent number: 6479642Abstract: The present invention relates generally to nucleic acids encoding a novel neuropeptide designated cortistatin. The cortistatin nucleic acids, proteins and polypeptides thereof along with anti-cortistatin antibodies are useful in both screening methods, diagnostic methods and therapeutic methods related to modulation of sleep and disorders thereof.Type: GrantFiled: May 15, 1997Date of Patent: November 12, 2002Assignee: The Scripps Research InstituteInventors: J. Gregor Sutcliffe, Luis De Lecea, Steven J. Henriksen, George R. Siggins
-
Patent number: 6479256Abstract: Disclosed are novel seven transmembrane receptor polypeptides having characteristic extracellular structure including lectin-binding, olfactomedin-like and mucin-like domains.Type: GrantFiled: March 4, 1999Date of Patent: November 12, 2002Assignee: ICOS CorporationInventor: Joel S. Hayflick
-
Patent number: 6479459Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.Type: GrantFiled: October 29, 1996Date of Patent: November 12, 2002Assignee: Immunex CorporationInventors: Douglas P. Cerretti, Pranhitha Reddy
-
Patent number: 6479261Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (a.a.119 to 133) have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide.Type: GrantFiled: November 15, 1995Date of Patent: November 12, 2002Assignee: Pharmacia CorporationInventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter Olins, Kumnan Paik, Joseph Polazzi, John Warren Thomas
-
Patent number: 6475745Abstract: The present invention is directed to screening for an agent that inhibits the effect of a neurotoxin from a plaque component activated mononuclear phagocyte on a neuron. In addition, the present invention is directed to methods of screening for agents that inhibit mononuclear phagocyte-plaque component complex formation, plaque component activation of a mononuclear phagocyte, plaque component induced neurotoxicity of a mononuclear phagocyte. An agent obtained by the method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation and a pharmaceutical composition comprising the agent are embodied by the present invention.Type: GrantFiled: September 3, 1997Date of Patent: November 5, 2002Assignee: Baylor College of MedicineInventor: Dana Giulian
-
Patent number: 6475747Abstract: Methods for detecting parasites, such as Cryptosporidium parvum, in turbid and non-turbid samples by solubilizing molecular markers or antigens of the parasite. The molecular markers are solubilized by incubating a sample containing the parasite with a solubilization buffer and detecting the solubilized antigens by electrochemiluminescence. The solubilization buffer contains one or more detergents alone or in combination with one or more denaturing agents in a buffered solution. The methods are an improvement over existing immunofluorescence assays for C. parvum because the methods described herein are quantitative, reproducible, have high sensitivity, are not labor-intensive, require only minimal sample processing, and avoid being adversely affected by sample turbidity. In addition, by using a electrochemiluminescence assay, microscopy is not required.Type: GrantFiled: October 28, 1997Date of Patent: November 5, 2002Assignees: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Victor C. W. Tsang, Yeuk-Mui Lee, Patrick W. Johnson, Michael J. Arrowood, Jeffrey L. Call
-
Patent number: 6475742Abstract: The present invention is directed to screening for an agent that inhibits the effect of a neurotoxin from a plaque component activated mononuclear phagocyte on a neuron. In addition, the present invention is directed to methods of screening for agents that inhibit mononuclear phagocyte-plaque component complex formation, plaque component activation of a mononuclear phagocyte, plaque component induced neurotoxicity of a mononuclear phagocyte. An agent obtained by the method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation and a pharmaceutical composition comprising the agent are embodied by the present invention.Type: GrantFiled: September 3, 1997Date of Patent: November 5, 2002Assignee: Baylor College of MedicineInventor: Dana Giulian
-
Patent number: 6475791Abstract: Methods disclosed herein capitalize on the ability of DNA Structure Specific Recognition Proteins (SSRPs) to bind to genomic lesions formed by chemotherapeutic agents, particularly cisplatin-type agents. Methods are provided for predicting whether an agent that damages DNA will also be cytotoxic, and for predicting whether particular eukaryotic cells will be susceptible to killing by a genotoxic drug. A screening method is provided for identifying new genotoxic drugs that produce SSRP-recognized lesions in DNA. Methods also are provided for sensitizing particular eukaryotic cells to killing by chemotherapeutic agents, particularly cisplatin-type drugs.Type: GrantFiled: June 2, 1997Date of Patent: November 5, 2002Assignee: Massachusetts Institute of TechnologyInventors: Stephen J. Lippard, John M. Essigmann, Brian A. Donahue, Jeffrey H. Toney, Suzanne L. Bruhn, Pieter M. Pil, Steven J. Brown, Patti J. Kellett
-
Patent number: 6476213Abstract: The present application relates to nucleotide sequences which regulate the biosynthesis of the flagella proteins Helicobacter pylori, to the proteins encoded by these sequences and to aflagellate bacterial strains. The invention also relates to the use of these means for detecting an infection due to H . pylori or for protecting against such an infection.Type: GrantFiled: June 28, 1996Date of Patent: November 5, 2002Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche MedicaleInventors: Sebastian Suerbaum, Agnès Labigne
-
Patent number: 6476001Abstract: Neural injury may be advantageously treated with CM101, a polysaccharide toxin isolated from Group B &bgr;-hemolytic Streptococcus bacteria. CM1O1 treatment aids in the re-establishment of neuronal connectivity, at least partially inhibits scar formation, and increases the probability of survival during the critical period following injury to the central nervous system. Preexisting neural injuries having scar tissue are ameliorated by surgical excision of the scar tissue in conjunction with administration of CM101.Type: GrantFiled: July 29, 1999Date of Patent: November 5, 2002Assignee: Vanderbilt UniversityInventors: Carl G. Hellerqvist, Artur W. Wamil, Barbara D. Wamil
-
Patent number: 6475752Abstract: The invention provide a mammalian nucleic acid molecule and fragments thereof. It also provides for the use of the mammalian nucleic acid molecule for the characterization, diagnosis, evaluation, treatment, or prevention of conditions, diseases and disorders associated with its expression and for the production of a model system. The invention additionally provides expression vectors and host cells for the production of the protein encoded by the mammalian nucleic acid molecule. The invention further provides a mammalian protein or portions thereof. The invention still further provides for the use of the nucleic acid molecule and protein in assays to detect or purify ligands.Type: GrantFiled: July 30, 1999Date of Patent: November 5, 2002Assignee: Incyte Genomics, Inc.Inventors: Preeti Lal, Y. Tom Tang, Mariah R. Baughn, Matthew R. Kaser
-
Patent number: 6472178Abstract: Modified ciliary neurotrophic factor, methods for production and methods of use, especially in the treatment of Huntington's disease, obesity, and gestational or adult onset diabetes.Type: GrantFiled: February 27, 1998Date of Patent: October 29, 2002Assignee: Regeneron Pharmaceuticals, Inc.Inventors: James P. Fandl, Neil E. Stahl, Stanley J. Wiegand
-
Patent number: 6472512Abstract: The present invention relates to a novel KDI protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a human interferon polypeptide, called “KDI”. KDI polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of KDI activity. Also provided are therapeutic methods for treating immune system-related disorders.Type: GrantFiled: July 20, 2001Date of Patent: October 29, 2002Assignee: Human Genome Sciences, Inc.Inventors: David W. LaFleur, Paul A. Moore, Steven M. Ruben